{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:17:36Z","timestamp":1791494256680,"version":"4.3.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.crohns.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T04:01:38Z","timestamp":1333598498000},"page":"369-376","source":"Crossref","is-referenced-by-count":90,"title":["Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease"],"prefix":"10.1093","volume":"7","author":[{"given":"Amit","family":"Assa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Broide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Zevit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bujanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raanan","family":"Shamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2012.03.006_bb0005","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.03.006_bb0010","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.03.006_bb0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2012.03.006_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease","volume":"98","author":"Baldassano","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00005176-200305000-00007","article-title":"A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease","volume":"36","author":"Cezard","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2012.03.006_bb0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","article-title":"Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease","volume":"36","author":"Borrelli","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ibd.20329","article-title":"Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort","volume":"14","author":"de Ridder","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0040","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.03.006_bb0045","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.20845","article-title":"Long-term outcome of maintenance infliximab therapy in children with Crohn's disease","volume":"15","author":"Hyams","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2010.04507.x","article-title":"The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited","volume":"33","author":"de Bie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.03.006_bb0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1185\/03007995.2010.547575","article-title":"Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension","volume":"27","author":"Hyams","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.crohns.2012.03.006_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MCG.0b013e3181ebaef9","article-title":"Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose \u201cescalation\u201d in patients losing response","volume":"45","author":"Chaparro","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0065","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ibd.21615","article-title":"Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study","volume":"17","author":"Cromb\u00e9","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0070","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/ibd.20534","article-title":"Short-term response to adalimumab in childhood inflammatory bowel disease","volume":"14","author":"Noe","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0075","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/ajg.2009.372","article-title":"Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease","volume":"104","author":"Viola","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10620-009-0791-7","article-title":"Adalimumab treatment in children with refractory Crohn's disease","volume":"55","author":"Rosenbach","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2012.03.006_bb0085","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2036.2011.04603.x","article-title":"A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease","volume":"33","author":"Rusell","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.03.006_bb0090","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/ajg.2009.493","article-title":"Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease","volume":"104","author":"Rosh","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.03.006_bb0105","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/j.1572-0241.2000.03263.x","article-title":"Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease","volume":"95","author":"Kugathasan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","article-title":"Response to infliximab is related to disease duration in paediatric Crohn's disease","volume":"18","author":"Lionetti","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.03.006_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00384-008-0578-x","article-title":"Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients","volume":"24","author":"Diamanti","year":"2009","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0120","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1440-1746.2009.06195.x","article-title":"Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease","volume":"25","author":"Sinitsky","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MPG.0b013e3181edd797","article-title":"Improvement of growth of children with Crohn's disease following anti-TNF-\u03b1 therapy can be independent of pubertal progress and glucocorticoid reduction","volume":"52","author":"Malik","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2012.03.006_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ibd.20069","article-title":"Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease","volume":"13","author":"Walters","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MPG.0b013e318175ca7f","article-title":"Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms","volume":"48","author":"Pfefferkorn","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2012.03.006_bb0140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MPG.0b013e3181957a11","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update","volume":"48","author":"Mackey","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2012.03.006_bb0145","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2012.03.006_bb0155","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0160","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/MEG.0b013e3282f16251","article-title":"Resistin is an inflammatory marker of inflammatory bowel disease in humans","volume":"19","author":"Konrad","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0165","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.4049\/jimmunol.174.9.5789","article-title":"Resistin, an adipokine with potent proinflammatory properties","volume":"174","author":"Bokarewa","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nut.2008.07.020","article-title":"Circulating adipokines and the protective effect of hyperinsulinemia in inflammatory bowel disease","volume":"25","author":"Valentini","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.crohns.2012.03.006_bb0175","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ibd.21091","article-title":"Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease","volume":"16","author":"Weigert","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0180","first-page":"CD006893","article-title":"Tumor necrosis factor-alpha antibodies for maintenance of remission in Crohn's disease","volume":"23","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.crohns.2012.03.006_bb0185","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/BF02088741","article-title":"Increased energy expenditure in growing adolescents with Crohn's disease","volume":"41","author":"Zoli","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2012.03.006_bb0190","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/gut.46.5.695","article-title":"Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis","volume":"46","author":"Ballinger","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2012.03.006_bb0195","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1084\/jem.167.3.1211","article-title":"Cachectin\/tumor necrosis factor induces cachexia, anemia, and inflammation","volume":"167","author":"Tracey","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.crohns.2012.03.006_bb0200","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1053\/j.gastro.2005.02.003","article-title":"Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis","volume":"128","author":"DiFedele","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.03.006_bb0205","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2010.04.044","article-title":"Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease","volume":"139","author":"Thayu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.03.006_bb0210","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/ajg.2010.20","article-title":"Nutritional status and growth in pediatric Crohn's disease: a population-based study","volume":"105","author":"Vasseur","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0215","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/ibd.20931","article-title":"Effect of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease","volume":"15","author":"Parmentier-Decrucq","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.03.006_bb0220","doi-asserted-by":"crossref","first-page":"11817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.03.006_bb0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.03.006_bb0230","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0235","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3109\/00365521.2010.539253","article-title":"Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy","volume":"46","author":"Lonnkvist","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0240","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","article-title":"Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis","volume":"12","author":"Fagan","year":"1982","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.crohns.2012.03.006_bb0245","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/MEG.0b013e32832b125c","article-title":"Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5years","volume":"21","author":"Lonnkvist","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.03.006_bb0250","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/ibd.20924","article-title":"Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab","volume":"15","author":"Afif","year":"2009","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S187399461200133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S187399461200133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/7\/5\/369\/1073270\/7-5-369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T21:16:28Z","timestamp":1503436588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2012.03.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S187399461200133X"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2012.03.006","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}